Dubbed by some as “a walking bull” Generex Biotechnology Corporation (GNBT) has seen several days of active trading and increased share price. In fact, for the majority of 2015, the stock has seen a healthy increase in price prior to the recent jump. On April 21 GNBT announced presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse.
AE37 is being developed by Antigen Express, Inc. a wholly-owned subsidiary of Generex. The presentation was made at the American Association for Cancer Research Annual Meeting held in Philadelphia, PA from April 18 to 22.
Results were shown as being encouraging for both breast and prostate cancer trials of AE37 and were thought to warrant continued clinical development for mono as well as combination therapy. According to the company, GNBT plans to disclose the latest Phase II results at the 2015 American Society of Clinical Oncology Annual Meeting held at the end of May.
Generex’s proprietary liquid formulations and delivery method through the RapidMist device allow drugs that are typically injected to be received orally as a spray. On April 23 the company announced that it has entered into a non-binding Letter of Intent to license the Generex proprietary RapidMist™ drug delivery technologies to Smoofi, Inc. (www.smoofi.com) (SMFI) for the delivery of medicinal and recreational cannabis derived products into the bloodstream through the buccal membrane.
In addition to traditional biotech, GNBT has thrown its hat into the cannabis sector following the announcement that it had acquired a minority interest in CannScience, a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.
Generex, Smoofie, and CannScience believe that “absorption of cannabis derived products through the buccal membrane offers distinct advantages to alternative routes of administration – principally, a faster onset of activity compared to oral administration, higher level of control for dosing, and more predictable absorption and pharmacodynamics.”